The PBAC recently made a recommendation to allow biologics to be substituted with biosimilar drugs by clinicians and pharmacists if the biosimilar is found to be a safe and effective equivalent treatment.
For further information refer to: Statement from PBAC safety of biosimilars
A biosimilar or similar biological medicinal product (SBMP) is a version of an already registered biological medicine that:
- has a demonstrable similarity in physicochemical, biological and immunological characteristics, efficacy and safety, based on comprehensive comparability studies
- has been evaluated by the TGA according to this guideline and other relevant EU guidelines adopted by the TGA.
For up to date information of Biosimilar medicines refer to the TGA website http://www.tga.gov.au/book/what-biosimilar
Other sources of information:
ADEA Fact Sheets
- A Diabetes Educator or a Credentialled Diabetes Educator? – October 2013